Introduction
============

*Pseudomonas aeruginosa* is a Gram-negative ubiquitous microorganism. It can be found in various environmental ecological niches (e.g., water, soil, and plants) but can also infect humans ([@B4]). It more specifically affects individuals with impaired defenses such as patients with severe burns, cancer or cystic fibrosis ([@B13]). *P. aeruginosa* is innately resistant to a large number of commercially available antibiotics ([@B34]) and, like most other species of bacteria, has acquired a wide array of resistance mechanisms, tremendously complicating the clinical handling of *P. aeruginosa* infections and leading to the emergence of so-called pan resistant strains ([@B3]; [@B34]). Modification of the membrane permeability is one of the mechanisms by which Gram-negative bacteria can decrease their susceptibility to antibiotics, by a reduction in the antibiotic entry through outer membrane porins and/or an increase in antibiotic efflux through efflux pumps (EPs). For example, in *P. aeruginosa*, mutations in the porin OprD can lead to the resistance to carbapenems ([@B43]; [@B8]). Overexpression of EPs belonging to the Resistance-Nodulation-Division (RND) family, i.e., MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM, has also been pointed out as a resistance mechanism toward various antibiotic families such as β-lactams, aminoglycosides or fluoroquinolones (FQ) ([@B34]). Additionally, an inverse association between the expressions of *oprD* and genes encoding RND EPs has been pointed out in carbapenem-resistant *P.aeruginosa* strains ([@B17]; [@B16]; [@B42]; [@B21]). It was demonstrated that MexT, a positive regulator of *mexEF-OprN* expression, negatively regulates the expression of OprD in carbapenem-resistant strains ([@B17]).

RND EPs are constituted by three proteins: the first one is acting as an outer membrane channel \[a protein belonging to the outer membrane factor (OMF) family, e.g., OprM\], the pump itself is embedded in the cytoplasmic membrane (the actual RND protein of the pump, e.g., MexB) and, in the periplasmic space, a linker protein is joining the first two proteins \[this protein is also referred to as the major facilitator protein (MFP), e.g., MexA\] ([@B32]). These pumps are involved in *P. aeruginosa* physiological functions such as quorum-sensing ([@B29]), biofilm formation ([@B1]) and virulence factors ([@B2]; [@B9]). Expression and overexpression have been described when a mutation occurs in the repressor/activator gene sequences commanding the operons encoding EPs ([@B34]; [@B24]). Useful details on the systems regulating EP expression in *P. aeruginosa* can be found in reviews such as [@B34] and [@B31]. The aim of the present work was to assess the expression of OprD and RND EPs was different in clinical strains resistant to ciprofloxacin (CIP), a molecule belonging to the fluoroquinolone (FQ) family and in *P. aeruginosa* strains retrieved from non-clinical (mainly environmental) samples isolated from a hospital background. Phenotypic resistance to CIP was chosen as a tracker for the overexpression of EPs as FQs are good substrates for the four major RND pumps found in *P. aeruginosa* ([@B34]). Assessing whether the CIP phenotypic resistance profile of *P. aeruginosa* strains could be related to the expression of one or several genes encoding for the major RND EPs could be helpful to evaluate the *in vitro* efficacy of new potential efflux pump inhibitors on relevant clinical strains resistant to this molecule.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

Thirty-three clinical strains of *P. aeruginosa* resistant to ciprofloxacin (CIP) isolated from 33 patients of Amiens University Hospital (France) were collected over a 5-month period and included in this study. The selection of these clinical strains was made by screening the results of all in-coming clinical samples (no specific unit or ward targeted) and retaining *P. aeruginosa* strains detected as resistant to CIP (CIP-R) by the disk diffusion method used routinely. If multiple samples yielded a ciprofloxacin-resistant strain for a given subject, only one isolate was included in the panel of strains. Resistance was confirmed through minimum inhibitory concentration (MIC) determination. MICs were determined over a range of 0.0625 to 128 μg/mL on 96-microwell plates using the broth microdilution technique in cation-adjusted Mueller-Hinton ([@B7]). Resistance to CIP was determined for MICs of 1 μg/mL and above, according to EUCAST latest breakpoints ([@B11]).

Environmental strains consisted of *P. aeruginosa* strains previously isolated from non-clinical samples and retrieved from the culture collection of Amiens University Hospital as well as strains prospectively obtained over a 2-year period (May 2016--May 2018) from water samples systematically collected as part of the program for water quality monitoring in Amiens University Hospital and surrounding hospitals. This program includes the detection of *P. aeruginosa* on a cetrimide agar (Biomérieux, Marcy-l'Etoile, France) according to the current ISO guidelines ([@B10]) and is based on a bi-annual sampling of critical control points of the hospital water supply system. Overall, 208 critical control points have been identified through an internal risk analysis and are sampled routinely.

A target number of 30 strains for each group (clinical and non-clinical) was set at the beginning of the study. While this target was easily met for clinical strains, the prospective collection of environmental strains originating from the water quality monitoring program was slow going. As only five *P. aeruginosa* strains had been isolated at the end of 2016, it was decided to include *P. aeruginosa* strains previously isolated from the environment and as well as non-clinical samples that had been kept in the laboratory collection in addition to the prospective collection of such strains. A total of 30 non-clinical strains was reached in May 2018.

Two strains were considered for the role of reference (calibrator) in RT-qPCR assays: a strain (AM19) from the same clinical background as CIP-R strains but susceptible to CIP and *P. aeruginosa* DSM (Deutsche Sammlung für Mikroorganismen und Zellkulturen, Braunschweig, Germany) 1117/ATCC (American Type Culture Collection) 27853, a reference *P. aeruginosa* strain used as quality control in antimicrobial susceptibility testing ([@B12]). All strains were kept frozen at -80°C on microbeads (WVR International SAS, Fontenay-sous-Bois, France) until use.

Ciprofloxacin Minimum Inhibitory Concentration (MIC) and Phenotypic Efflux Determination
----------------------------------------------------------------------------------------

PAβN (Sigma-Aldrich, Saint-Quentin-Fallavier, France) has been described as an efflux pump inhibitor (EPI) affecting MexAB-OprM, MexCD-OprJ and MexEF-OprN EPs ([@B23]) and has also been shown to reduce levofloxacin MIC in a *P. aeruginosa* strain with an increased MexXY activity ([@B25]). This molecule was subsequently used as such to phenotype-wise determine the prevalence of efflux pump-mediated resistance to fluoroquinolones in *P. aeruginosa.* It was added to the standard MIC determination procedure at a fixed final concentration of 50 μg/mL ([@B37]). MIC determination for PAβN was also carried out for all strains over concentrations ranging from 0.1 to 200 μg/mL, to ascertain that the 50 μg/mL concentration used for EP inhibition was not inhibitory in itself. The phenotypic efflux was deemed significant when the MIC determined in the presence of PAβN was at least fourfold lower than the MIC witnessed in its absence ([@B32]; [@B37]), leading to a calculated phenotypic efflux factor (MIC without PAβN/MIC with PAβN) of four and above.

RNA Extraction and Reverse Transcription
----------------------------------------

Strains were cultured in cation adjusted Mueller-Hinton Broth (Merck, Darmstadt, Germany) for 18 to 24 h at 37°C up to the late exponential phase prior to EP expression determination. Total RNA extraction was carried out using the Qiagen RNeasy purification kit with the addition of RNAprotect Bacteria Reagent (Qiagen, Courtaboeuf, France). Briefly, 1 mL of culture medium was centrifuged (8000 *g*, 5 min), the bacterial pellet resuspended in 1 mL of RNAprotect reagent and left to incubate at room temperature for 5 min. After decantation of the RNAprotect reagent (8000 *g*, 10 min), 200 μL of Tris 30 mM-EDTA 1 mM (pH 8.0) buffer containing lysozyme (15 mg/mL) and proteinase K (0.56 mg per strain) were added and incubated for 10 min at room temperature to ensure a complete bacterial cell wall lysis. Further precipitation and purification of nucleic acids were performed according to the manufacturer's recommendations and the final elution step carried out using 50 μL RNase-free water. After checking the RNA extraction quality on a 1% agarose gel and measuring the RNA content (Nanodrop, ThermoFisher Scientific, France), RNA extracts were stored at -20°C until further use.

Prior to cDNA synthesis, genomic DNA was removed from 1 μg of total RNA using the gDNA wipeout buffer included in the Quantitect^®^ Reverse Transcription kit (Qiagen). The reverse transcription was performed under a volume of 20 μL including 14 μL of template RNA (extract concentrations adjusted to contain 1 μg of RNA), 1 μL of reverse transcription master mix, 4 μL RT buffer 5x (containing dNTPs and Mg^2+^) and 1 μL of RT primer mix containing random hexamers. Reverse transcription was performed in a Veriti PCR Thermal Cycler (Applied Biosystems, France) for 30 min at 42°C followed by a 3 min incubation at 95°C to inactivate the reverse transcriptase.

All reactions including RNA handling were carried out on ice.

Real-Time PCR Assay
-------------------

Primers used in this study were designed using the Primer3 software available online^[1](#fn01){ref-type="fn"}^ and are listed in [Table 1](#T1){ref-type="table"}. As the genes encoding EP components are organized in operons ([@B35]; [@B30]), this work focused on the expression of *oprD* and *mexB*, *mexF*, *mexY* genes encoding the actual efflux pump protein of the three main RND EPs found in *P. aeruginosa.*

###### 

Primers used in this study.

  Gene     Amplicon size (bp)   Primer sequence (5′→ 3′) FWD/REV
  -------- -------------------- ----------------------------------
  *mexB*   167                  CAACATCCAGGACCCACTCT
                                AGGAAATCTGCACGTTCTGC
  *mexF*   163                  TGTACGCGAACGACTTCAAC
                                GAGGTGTCGCTGACCTTGAT
  *mexY*   159                  TCAGGCCGACCTTGAAGTAG
                                TCTCGGTGTTGATCGTGTTC
  *oprD*   157                  GCCGAAGCCGATATAATCAA
                                CATCTACCGCACAAACGATG
  *rpsL*   163                  TACTTCGAACGACCCTGCTT
                                TTTCCTCGTACATCGGTGGT
                                

Normalization of expression results was carried out using *rpsL* ([@B22]; [@B44]).

A Lightcycler 480 (Roche Diagnostics, Meylan, France) was used for all quantitative PCRs. All PCR amplification reactions were performed in 384-well-plates under a 10 μL final volume containing 2.5 μL of diluted (1:20) template cDNA, 1 μL of each primer (corresponding to a final concentration of 0.5 μM), 5 μL of Quantitect SYBR Green PCR Master Mix (including MgCl~2~ to reach to final concentration of 2.5 mM) (Qiagen) and 0.5 μL RNase/DNase free water (Qiagen).

The cycling program was set as follows : (1) activation : 1 cycle at 95°C for 15 min, (2) amplification : 45 cycles including a 15-s denaturation at 95°C, a 25-s annealing at 60°C and a 15-s elongation at 72°C, and (3) melting curve : 1 cycle including 5 s at 95°C, 1 min at 65°C and a final increase at 97°C with a transition rate of 0.11°C/s.

Each reaction was carried out in duplicate and the experiment was repeated on two different sets of RNA extracts (biological replicate).

Evaluation of Real-Time PCR Results
-----------------------------------

Relative standard curves describing the PCR efficiency (E) for each primer pair were generated for each amplicon ([@B20]).

Prior to any other analysis, melting curves were checked for the presence of primer dimers and other artifacts. The relative expression between the target and reference genes, was calculated using the formula (*E*\_*goi*^∧^(Δ*Ct*,*goi*))/(*E*\_*ref*^∧^(Δ*Ct*,*ref*)), where *E* stands for the PCR efficiency factor, *goi* for gene of interest and *ref* for reference.

Results were subsequently expressed as Normalized Calibrated Ratios (NCRs).

Statistical Analysis
--------------------

Differences in the expression of each gene of interest were tested using the single sample *t*-test vs. cut-off values of 0.5 for underexpression and 2 for overexpression, respectively ([@B38]). Differences in gene detection and expressions between clinical and non-clinical/environmental strains were assessed using Fisher's exact test.

Correlations between gene expressions, MICs with and without PAβN as well as with the MIC reduction factor were tested using Spearman's correlation coefficient.

Statistical significance was inferred for *p*-values below 0.05.

The statistical analysis was performed using VassarStats website^[2](#fn02){ref-type="fn"}^ and XLstat 2015 software (Addinsoft, France).

Ethics Statement
----------------

As strains were isolated from clinical samples routinely prescribed to patients by the medical staff in charge and as no specific sampling in order to collect *P. aeruginosa* strains was performed, no evaluation by the local ethics committee was sought. Additionally, written informed consent from the patients was not needed as this work was of a retrospective nature and as no information that could be linked to patients was included.

Results and Discussion
======================

Strain Collection, CIP MICs, and Phenotypic Efflux Factors
----------------------------------------------------------

[Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} summarize the origins, MICs with and without PAβN and the resulting calculated phenotypic efflux factor for each of the 33 CIP-R clinical strains and 30 non-clinical/environmental strains evaluated in this work, respectively. Only 3 (10%) these non-clinical/environmental strains were classified as resistant to CIP with a MIC of 1 μg/mL according to EUCAST 2018 standards ([@B11]).

###### 

Characteristics of the clinical strains included in this study, classified by increasing Ciprofloxacin (CIP) MIC.

  Strain    Clinical origin   CIP MIC (μg mL^-1^)   Phenotypic efflux factor^a^   RND pump gene overexpressed   
  --------- ----------------- --------------------- ----------------------------- ----------------------------- --------------------
  AM19      Urinary tract     \<0.0625              ND^b^                         ND                            Reference strain
  DSM1117   Blood culture     0.125                 ND                            ND                            *mexB*
  AM126     Rectal swab       2                     0.25                          8                             *mexB*
  AM3       Blood culture     2                     0.0625                        32                            *mexB*
  AM60      Tracheal          2                     0.0625                        32                            *mexB*
  AM99      Sputum            2                     0.0625                        32                            *mexY*
  AM17      Sputum            4                     1                             4                             *mexF*
  AM74      Skin wound        4                     0.5                           8                             *mexB, mexY*
  AM33      Sinus             4                     0.0625                        64                            *mexB*
  AM66      Peritoneum        4                     0.0625                        64                            None
  AM83      Urinary tract     8                     2                             4                             *mexY*
  AM100     Ear               8                     4                             2                             None
  AM131     Rectal swab       8                     2                             4                             None
  AM32      Ear               16                    4                             4                             None
  AM44      Urinary tract     16                    4                             4                             *mexY*
  AM50      Urinary tract     16                    4                             4                             *mexY*
  AM52      Urinary tract     16                    2                             8                             *mexY*
  AM56      Ear               16                    2                             8                             *mexB*
  AM86      Tracheal          16                    2                             8                             *mexB*
  AM88      Urinary tract     16                    2                             8                             *mexY*
  AM115     Urinary tract     16                    2                             8                             *mexB*
  AM127     Rectal swab       16                    2                             8                             None
  AM1       Blood culture     16                    1                             16                            None
  AM27      Tracheal          16                    1                             16                            *mexF, mexY*
  AM85      Sputum            16                    1                             16                            *mexB, mexF, mexY*
  AM10      Urinary tract     32                    8                             4                             *mexY*
  AM42      Urinary tract     32                    8                             4                             *mexF,mexY*
  AM130     Rectal swab       32                    8                             4                             None
  AM13      Urinary tract     32                    4                             8                             None
  AM110     Sputum            32                    4                             8                             *mexY*
  AM128     Rectal swab       64                    16                            4                             None
  AM129     Rectal swab       64                    16                            4                             None
  AM69      Tracheal          64                    16                            4                             *mexY*
  AM113     Prepuce           64                    8                             8                             *mexY*
  AM58      Urinary tract     128                   64                            2                             *mexY*
                                                                                                                

a

MIC without PAβN/MIC with PAβN.

b

Not determined.

###### 

Characteristics of non-clinical/environmental strains included in this study, classified by increasing Ciprofloxacin (CIP) MIC.

  Strain   Environmental origin, town          Sampling date   CIP MIC (μg mL^-1^)   Phenotypic efflux factor   RND pump gene overexpressed   
  -------- ----------------------------------- --------------- --------------------- -------------------------- ----------------------------- ------
  ENV1     Water, Amiens                       2016            \<0.0625              ND                         --                            None
  ENV2     Water, Amiens                       2016            \<0.0625              ND                         --                            None
  ENV3     Human milk, Amiens                  2016            \<0.0625              ND                         --                            None
  ENV8     Siphon, Amiens                      2016            \<0.0625              ND                         --                            None
  ENV9     Siphon, Amiens                      2016            \<0.0625              ND                         --                            None
  ENV12    Water, Amiens                       1995            \<0.0625              ND                         --                            None
  ENV18    Water, Amiens                       1997            \<0.0625              ND                         --                            None
  ENV19    Water, Amiens                       1997            \<0.0625              ND                         --                            None
  ENV20    Water, Amiens                       1997            \<0.0625              ND                         --                            None
  ENV4     Siphon, Amiens                      2016            0.125                 ND                         --                            None
  ENV5     Endoscope, Amiens                   2016            0.125                 ND                         --                            None
  ENV6     Water, Amiens                       2016            0.125                 ND                         --                            None
  ENV7     Water, Amiens                       2016            0.125                 ND                         --                            None
  ENV23    Endoscope, Amiens                   2017            0.125                 ND                         --                            None
  ENV24    Water, Amiens                       2017            0.125                 ND                         --                            None
  ENV25    Water, Albert                       2017            0.125                 ND                         --                            None
  ENV27    Water, Amiens                       2018            0.125                 ND                         --                            None
  ENV30    Water, Amiens                       2018            0.125                 ND                         --                            None
  ENV13    Irrigation medical device, Amiens   1995            0.125                 ND                         --                            None
  ENV10    Siphon, Amiens                      2016            0.25                  ND                         --                            None
  ENV26    Water, Amiens                       2018            0.25                  ND                         --                            None
  ENV28    Water, Amiens                       2018            0.25                  ND                         --                            None
  ENV29    Water, Amiens                       2018            0.25                  ND                         --                            None
  ENV11    Water, Doullens                     2016            0.5                   \<0.0625                   \>8                           None
  ENV14    Water, Amiens                       1997            0.5                   \<0.0625                   \>8                           None
  ENV15    Water, Amiens                       1997            0.5                   \<0.0625                   \>8                           None
  ENV16    Water, Amiens                       1997            0.5                   \<0.0625                   \>8                           None
  ENV17    Siphon, Amiens                      1997            1                     \<0.0625                   \>16                          None
  ENV21    Water, Amiens                       1999            1                     \<0.0625                   \>16                          None
  ENV22    Water, Amiens                       1999            1                     \<0.0625                   \>16                          None
                                                                                                                                              

Most (31/33, ∼94%) CIP-R clinical strains displayed a phenotypic efflux factor of four or above ([Table 2](#T2){ref-type="table"}). All threeCIP-R environmental strains had a phenotypic efflux factor above 16 ([Table 3](#T3){ref-type="table"}). The lower phenotypic efflux factor witnessed in clinical strains could be explained by a resistance only partly mediated through an increased efflux. Indeed, the higher MICs (up to 128 μg/mL) in clinical strains might be linked to cumulative mutations in CIP targets, DNA gyrase and topoisomerase IV proteins, as described previously ([@B6]; [@B36]). In the environmental strains, efflux could be the sole mechanism supporting the rise of the MIC up to 1 μg/mL. Determination of QRDR mutation frequencies in the environmental strains included in this study would have reinforced this hypothesis. Nevertheless, the study by [@B6] has already shown that most QRDR mutations lead to CIP MICs equal or superior to 1 μg/mL while strains only overexpressing EPs displayed a maximum MIC of 2 μg/mL. Our results are therefore in line with this report. Also, they are in agreement with a theory stating that the overexpression of EPs could act as a first-step mutation, leading to subsequent ones in DNA gyrase and topoisomerase IV proteins and higher levels of CIP resistance ([@B18]; [@B41]).

EP Gene Overexpression
----------------------

First, gene expression was compared between the two CIP-susceptible strains included in this work as possible calibrators for NCR calculations. *P. aeruginosa* DSM1117, a clinical strain from a culture collection used in antibiotic testing ([@B11]), displayed a significant overexpression of *mexB* and underexpression of *mexY* as compared to the clinical strain AM 19 ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). The reasons for choosing *P. aeruginosa* AM19 over *P. aeruginosa* DSM1117 as a calibrator in our calculations were that (i) AM19 came from a similar background as the other strains enrolled in this study and (ii) *oprD* expression was not detected in *P. aeruginosa* DSM1117 and would therefore not allow the calculation of NCRs for this gene. Thereafter, individual NCRs were calculated as mean ± sem (standard error of the mean) for each strain, using *P. aeruginosa* AM19 as calibrator ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). If *P. aeruginosa* DSM1117 had been chosen as a calibrator, the potential differences in NCRs results for EP genes would have been (i) a greater frequency of overexpression for *mexY* gene in clinical strains, as it was underexpressed in *P. aeruginosa* DSM1117 as compared to *P. aeruginosa* AM19, and (ii) a lower frequency of *mexB* overexpression in clinical strains ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). As for non-clinical strains, the results would have remained similar, EP gene expressions being overall low among these strains.

At least one EP was overexpressed in 23 (70%) out of the 33 clinical strains included in this work ([Table 2](#T2){ref-type="table"}). One could argue that the mRNA expression level for a given gene is not directly related to the actual amount of protein produced by the bacteria. However, [@B44] previously showed a good correlation between the amounts of MexY and MexB proteins and their respective mRNA expressions.

[@B14] reported a simultaneous overexpression of MexAB-OprM and MexXY in a set of ticarcillin-resistant clinical strains originating from 15 French hospitals. No such joint overexpression was witnessed for the CIP-R strains in this study. Only three clinical strains overexpressed two EPs simultaneously (*mexF/mexY* for two strains and *mexB/mexY* for one). Additionally, a single clinical strain overexpressed all three RND genes tested in this work ([Table 2](#T2){ref-type="table"}).

A high prevalence of *mexY* overexpression was witnessed in the series of clinical strains ([Table 4](#T4){ref-type="table"}). MexXY expression has been shown to be regulated by repressor MexZ but also by an independent two-component system, ParRS ([@B31]). The frequent overexpression of *mexY* witnessed here might therefore be linked to mutation(s) in this repressor sequence and/or the triggering of ParRS system. MexAB-OprM appeared to be either up- or down-regulated ([Table 4](#T4){ref-type="table"}). Similar results were reported in multidrug-resistant strains of *P. aeruginosa* in Bulgaria ([@B40]). Only four clinical strains were found to overexpress MexEF-OprN ([Table 3](#T3){ref-type="table"}), ruling out its role as a major contributor to CIP efflux mediated resistance.

###### 

Efflux pump genes and *oprD* detection and expression in clinical (*n* = 33) and non-clinical (*n* = 30) *Pseudomonas aeruginosa* strains isolated in this study.

                                   *mexB*        *mexF*        *mexY*         *oprD*
  -------------------------------- ------------- ------------- -------------- ---------
  **Positive RT-qPCR detection**                                              
  Overall                          54 (86)^a^    52 (83)       57 (90)        29 (46)
  Clinical                         33 (100)^∗^   32 (97)^∗∗^   33 (100)^∗∗^   15 (45)
  Non-clinical                     21 (70)^∗^    20 (67)^∗∗^   24 (80)^∗∗^    14 (47)
  **Overexpression**                                                          
  Overall                          9 (14)        4 (6)         15 (24)        0 (0)
  Clinical                         9 (27)^†^     4 (12)        15 (45)^∗^     0 (0)
  Non-clinical                     0 (0)^†^      0 (0)         0 (0)^∗^       0 (0)
  **Underexpression**                                                         
  Overall                          39 (62)       46 (73)       35 (56)        49 (78)
  Clinical                         11 (33)^∗^    18 (55)^†^    5 (15)^∗^      23 (70)
  Non-clinical                     28 (93)^∗^    28 (93)^†^    30 (100)^∗^    26 (87)
                                                                              

RT-qPCR detection was considered positive for a given gene when cycle thresholds and subsequent Normalized Calibrated Ratios could be calculated from the experiments.

a

Number of strains (%).

∗

Significant difference between clinical and non-clinical strains (p \< 0.0001, Fisher's exact test).

∗∗

Significant difference between clinical and non-clinical strains (p \< 0.001, Fisher's exact test).

†

Significant difference between clinical and non-clinical strains (p \< 0.01, Fisher's exact test).

A positive correlation was found between *mexB* and *mexF* expressions (Pearson's *r* = 0.557, *p* = 0.001). This result is at odds with regulation pathways previously described. Indeed, in addition to mutations in its negative regulators MexR, NalC, and NalD, the overexpression of MexB has been linked with quorum-sensing signaling ([@B27]; [@B34]). Quorum-sensing autoinducers were shown to be implied in an inverse regulation of *mexB* and *mexF* expressions along with MexR and MexT regulators ([@B27]). However, the interplay between *mexF* and *mexB* might not be so straightforward as (i) other reports also describe a simultaneous overexpression of MexAB-OprM and MexEF-OprN ([@B38]) and (ii) other regulation pathways might be implied such as those including MexS, another regulator of MexEF-OprN ([@B39]).

The results for MexCD-OprJ were not included in this paper, as preliminary results for *mexD* expression in clinical strains showed that none of the strains displayed changes in the expression of this gene.

In contrast to clinical strains, none of the environmental strains overexpressed any EP ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and Supplmentary Table [S1](#SM1){ref-type="supplementary-material"}). Expression of RND EP genes in environmental *P. aeruginosa* strains is seldom reported in the literature ([@B5]; [@B26]). These studies showed that MexAB-OprM overexpression was linked to resistance to aztreonam and other β-lactams in *P. aeruginosa* strains isolated from agricultural soils and marine shellfish, respectively. They showed environmental strains can display features predisposing them to antibiotic resistance, which could, in turn, pose a threat to human and environmental health. This was not the case for the environmental strains included in this study.

Expression of *oprD* and Correlations the Expression of EP Genes
----------------------------------------------------------------

Only about 50% of the tested strains displayed detectable levels of *oprD* mRNA ([Table 4](#T4){ref-type="table"}). No significant difference was found in the distribution of *oprD* expression profiles between clinical and non-clinical strains ([Table 4](#T4){ref-type="table"}). Positive correlations were found with both *mexB* and *mexF* expressions (i) in clinical strains: *mexB/oprD* (Pearson's *r* = 0.417, *p* = 0.016) and *mexF/oprD* (*r* = 0.476, *p* = 0.005) and (ii) in environmental strains: *mexB/oprD* (Pearson's *r* = 0.494, *p* = 0.006) and *mexF/oprD* (*r* = 0.649, *p* \< 0.001, respectively).

An *oprD* repression has previously been reported as concomitant to MexAB-OprM, MexXY-OprM and MexEF-OprN overexpression in *P. aeruginosa* strains resistant to various β-lactams ([@B17]; [@B16]; [@B42]). Additionally, the link between *mexB* and *oprD* expressions in β-lactam resistant strains has been suggested to reflect an external pressure, such as antibiotic exposure, affecting both systems ([@B15]). However, the statistical significance of a possible correlation between these EPs and OprD expression remains to be ascertained in strains selected on the basis of other antibiotic resistances. For instance, in this study, no repression of *oprD* expression could be witnessed either in the CIP-R clinical *P. aeruginosa* strains when EPs are overexpressed.

Correlation Between the Expression of EP Genes, CIP MICs and the Phenotypic Efflux Factor
-----------------------------------------------------------------------------------------

As the growth stage has been shown to influence the expression levels of EP genes ([@B28]), *P. aeruginosa* strains were all grown up to the late exponential phase prior to RNA extraction to minimize variations and standardize culture conditions. This step insured the relevance of the correlation drawn between MICs and gene expression levels as MICs are classically determined after an 18 to 24-h incubation. CIP was used as a marker to detect efflux-mediated resistance to antibiotics as it has been shown to be a substrate for various EPs (e.g., NorA for *Staphylococcus aureus*, OqxAB for *Klebsiella pneumoniae*, AcrAB-TolC for *Escherichia coli*, AdeABC for *Acinetobacter baumannii*), including *P. aeruginosa* RND ones ([@B33]). When clinical and non-clinical strains were pooled together, CIP MICs were loosely correlated with *mexY* expression (Pearson's *r* = 0.400, *p* = 0.001). When the statistical analysis was held on clinical and environmental strains separately, no correlation between the expression of EP genes and MICs could be pointed out. For CIP-R clinical strains, a likely explanation for this lack of correlation is the presence of co-existing mutations in gyrase and topoisomerase IV proteins ([@B24]). Additionally, other parameters might also contribute to this lack of correlation such as resistance to aminoglycosides and/or β-lactams. Indeed, these antibiotic families are also known to be related to EPs' expression ([@B34]). It would therefore be interesting to further evaluate aminoglycosides and carbapenem resistances in these strains and the presence/absence of correlation with their expression of EPs.

To address a possible correlation between the reduction in CIP MICs in the presence of PAβN and EP expression, non-clinical strains were removed from the analysis as their initial low CIP MICs would not allow for a significant reduction ([Table 3](#T3){ref-type="table"}). Hence, for clinical strains, no statistically significant correlations between EP expression, the MIC reduction or the phenotypic efflux were detected. Therefore, CIP MICs in the presence of PAβN are not predictive of the overexpression of RND EPs in *P. aeruginosa.* Interfering factors such as a variable expression for other EPs and/or a decrease in MIC with PAβN not entirely linked with efflux inhibition could explain this lack of correlation. [@B19] indeed put forward that PAβN not only blocks EPs but also permeabilizes the outer membrane. In these conditions, entry of large antibiotics such as vancomycin and macrolides are facilitated. Such might also be the case for CIP (even though it is a smaller molecule which would not require outer membrane permeabilization to enter), hence further contributing to a reduction in apparent MICs. This might also explain why a high phenotypic efflux factor could be calculated for the three CIP-R environmental when no RND EP overexpression was detected in those strains. Nevertheless, this work enabled the description of clinical strains with various profiles of RND EP overexpression that will be used as laboratory tools for the evaluation of newly synthesized candidates for efflux pump inhibition.

To gain further insight in the relationships between the expression of RND EPs and phenotypic resistance to CIP in environmental strains, the collection of additional strains displaying such a resistance would be of interest as well as collecting strains from different hospitals to broaden the conclusions drawn from the results of this first study. It would also be interesting to investigate whether additional CIP susceptible clinical strains share the expression profile RND EPs' of their resistant counterparts or if their profile is closer to the one of environmental strains.

Conclusion
==========

The results obtained on the 33 clinical strains pertaining to this study showed that the main contributor to efflux-mediated CIP resistance was the MexXY EP. MexAB-OprM was either over- or under-expressed in clinical strains. *P. aeruginosa* strains isolated from Amiens hospital environment did not frequently display a high-level resistance to ciprofloxacin. However, the low-level resistance witnessed for some strains could not be linked with an overexpression of RND EPs. Indeed, RND EPs were significantly underexpressed in nearly all of the 30 non-clinical strains tested in this work. In contrast with what was previously described in carbapenem-resistant strains, a positive correlation between the expression of *oprD* and efflux pump genes *mexB* and *mexF* was witnessed in both CIP-R clinical environmental *P. aeruginosa* strains. A correlation limited to *mexY* expression was nevertheless witnessed for CIP MICs in the statistical analysis gathering the 63 clinical and environmental strains. However, no link with a specific EP component could be ascribed for the magnitude of the reduction in MICs generated by PAβN in the clinical strains. Therefore, no direct quantitative correlation can be made between this phenotypic trait and the genotypic overexpression of one or another of the three RND EPs tested here.
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